Irbesartan treatment does not influence plasma levels of the advanced glycation end products N ε(1-carboxymethyl)lysine and N ε(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3573-3577

  Engelen, Lian ^a,b   Persson, Frederik ^c   Ferreira, Isabel ^a,b   Rossing, Peter ^c   Hovind, Peter ^c,d   Teerlink, Tom ^e   Stehouwer, Coen D ^a,b   Parving, Hans Henrik ^f,g   Schalkwijk, Casper G ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STENO DIABETES CENTER   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Mental Health Center Glostrup   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

Author keywords

advanced glycation end products; albuminuria; angiotensin II type I receptor blockers; hypertension; irbesartan; type 2 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; IRBESARTAN; N EPSILON(1 CARBOXYMETHYL)LYSINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT DURATION;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; LYSINE; MALE; MIDDLE AGED; PROGNOSIS; TETRAZOLES;

EID: 80155172034     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr102     Document Type: Article

References (27)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21
3. Yamagishi S, Nakamura K, Matsui T et al. Inhibitors of advanced glycation end products (AGEs): Potential utility for the treatment of cardiovascular disease. Cardiovasc Ther 2008; 26: 50-58
4. Volpe M, Savoia C, De Paolis P et al. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13 (Suppl 3): S173-S178
5. Ruiz-Ortega M, Lorenzo O, Ruperez M et al. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001; 38: 1382-1387
6. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105: 30A-35.A.
7. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
8. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
9. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487
10. Forbes JM, ThomasMC, Thorpe SR et al. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 2004; S105-S107
11. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222
12. Fan Q, Liao J, Kobayashi M et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020
13. Izuhara Y, Sada T, Yanagisawa H et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28: 1767-1773
14. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984
15. Sugiyama T, Okuno T, Fukuhara M et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007; 85: 406-412
16. Komiya N, Hirose H, Saisho Y et al. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49: 681-689
17. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006; 74: 201-203
18. Monacelli F, Poggi A, Storace D et al. Effects of valsartan therapy on protein glycoxidation. Metabolism 2006; 55: 1619-1624
19. Busch M, Franke S, Wolf G et al. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108: C291-c297
20. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudy. Diabetes 2006; 55: 3550-3555
21. Ahmed N, Thornalley PJ. Advanced glycation endproducts: What is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233-245
22. WHO study group. Diabetes mellitus. WHO Tech Rep Ser 1985; 727: 1-104
23. Goldstein DE, Little RR, Wiedmeyer HM et al. Glycated hemoglobin: Methodologies and clinical applications. ClinChem1986; 32:B64-B70
24. Hofmann W, Guder WG. Preanalytical and analytical factors in determination of urinary IgG, albumin, a1-microglobulin and retinol-binding protein with the Behring nephelometer system (BNS). Lab Med 1989; 13: 470-478
25. Teerlink T, Barto R, Ten Brink HJ et al. Measurement of Nepsilon- (carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50: 1222-1228
26. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: Implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003; 419: 50-54
27. Miller AG, Tan G, Binger KJ et al. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 2010; 59: 3208-3215